Preclinical Imaging Market Size, Share & Trends Analysis Report By Product (CT Imaging, MRI Imaging, PET/SPECT Imaging, Multi-modal Imaging, Optical Imaging, Ultrasound Imaging, Photoacoustic Imaging, Reagents, Services), By Applications (Hospital, Diagnostics Center, Others), By End Use, By Region, and Segment Forecasts - 2035

Preclinical Imaging Market Overview

The preclinical imaging market size was valued at USD 2668.96 million in 2025 and is poised to grow from USD 2807.75 million in 2026 to USD 4429.95 million by 2035, growing at a CAGR of 5.2% during the forecast period 2026-2035.

The preclinical imaging market is expanding as pharmaceutical companies, biotechnology organizations, academic laboratories, contract research organizations, and translational research centers increase the use of non-invasive visualization technologies in drug discovery and disease-model studies. Imaging platforms now support repeated observation of anatomical, molecular, functional, metabolic, and physiological changes within the same research subject, improving longitudinal study design and reducing dependence on endpoint-only evaluation. CT Imaging, MRI Imaging, PET/SPECT Imaging, Multi-modal Imaging, Optical Imaging, Ultrasound Imaging, Photoacoustic Imaging, Reagents, and Services collectively address a broad spectrum of experimental requirements. Current systems increasingly combine multiple modalities, automated reconstruction, advanced quantification, artificial intelligence, low-dose scanning, high-sensitivity detectors, and compact benchtop configurations. Systems capable of submillimeter molecular imaging, rapid whole-body scans, and integrated PET/CT or PET/MR workflows are strengthening translational research. With the market projected to expand by approximately 57.8% between 2026 and 2035, laboratories are increasingly prioritizing platforms that improve reproducibility, throughput, animal welfare, and the speed at which preclinical findings can support clinical development decisions.

The United States represents a major center for preclinical imaging adoption because of its extensive pharmaceutical and biotechnology research ecosystem, large academic medical research network, strong federal and institutional research funding environment, and concentration of imaging technology developers. U.S. laboratories increasingly integrate MRI, micro-CT, optical imaging, PET, SPECT, ultrasound, and photoacoustic systems into oncology, neuroscience, cardiovascular, metabolic, immunology, infectious-disease, and regenerative-medicine studies. Demand is particularly strong for high-throughput systems that support longitudinal imaging and quantitative analysis across several experimental time points. The country is estimated to account for around 34% of global demand in 2026, supported by extensive translational research and early adoption of advanced imaging software. Researchers are also emphasizing low-radiation protocols, automation, multimodal co-registration, and standardized data processing. PET/CT platforms offering approximately 0.7 mm spatial resolution, sensitivity approaching 12%, and low-dose CT capabilities demonstrate the performance improvements influencing U.S. purchasing decisions. Expansion of precision medicine, radiopharmaceutical development, and AI-enabled analysis is expected to sustain the country's strategic importance through 2035.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: MRI Imaging is expected to remain a leading product category, accounting for approximately 22% of market demand as high-field systems support detailed anatomical, functional, neurological, cardiovascular, and longitudinal imaging without ionizing radiation.
• Leading Application: Hospital applications are projected to account for nearly 46% of overall demand, supported by affiliated research laboratories, translational medicine programs, advanced imaging infrastructure, and growing integration between preclinical investigation and clinical-development workflows.
• Leading Region: North America is expected to lead with approximately 39% market share in 2026, driven by intensive pharmaceutical R&D, established research universities, advanced imaging facilities, biotechnology investment, and rapid adoption of multimodal systems.
• Fastest Growing Region: Asia-Pacific is projected to record the strongest regional expansion at approximately 6.4% annual growth, supported by expanding biomedical research, pharmaceutical development, laboratory modernization, and increasing installation of sophisticated imaging equipment.
• Technology Trend: Multimodal imaging is gaining importance as researchers combine 2 or more complementary modalities, including PET/CT, PET/MR, SPECT/CT, optical/CT, and ultrasound-photoacoustic technologies, to obtain anatomical and molecular information within unified workflows.
• Market Driver: Pharmaceutical and biotechnology research intensity remains the primary growth driver, with the global market expected to add approximately USD 1622.2 million between 2026 and 2035 as drug developers increase longitudinal imaging use.
• Competitive Landscape: Competitive differentiation increasingly focuses on compact and modular systems, with commercially deployed benchtop platforms exceeding 250 installed units worldwide and supporting scalable combinations of PET, SPECT, and CT capabilities.
• Future Outlook: AI-supported image analysis, quantitative reconstruction, and integrated data workflows are expected to become increasingly important as the market approaches USD 4429.95 million by 2035 and laboratories prioritize faster, reproducible research decisions.

Latest Trends

Multimodal imaging is becoming one of the most influential trends in the preclinical imaging market because drug developers increasingly require simultaneous or sequential information regarding anatomy, molecular activity, physiology, metabolism, and therapeutic response. Rather than relying on a single modality, laboratories are combining PET with CT or MRI, SPECT with CT, optical imaging with structural imaging, and ultrasound with photoacoustic technologies. These approaches can improve localization, quantification, and interpretation while reducing uncertainty between separate experiments. Current PET/MR systems are available at magnetic field strengths extending to 9.4 T and can accommodate animal models weighing up to approximately 3 kg, while advanced PET/CT systems provide total-body fields of view reaching around 150 mm axially. Compact modular platforms are also reducing infrastructure requirements and enabling laboratories to expand imaging capability incrementally. More than 250 modular CUBES installations demonstrate growing acceptance of flexible benchtop architecture. These developments are increasing accessibility while allowing researchers to select combinations appropriate for oncology, neurology, cardiovascular disease, immunology, and radiopharmaceutical research.

Artificial intelligence, automated reconstruction, low-dose imaging, higher detector sensitivity, and software-based harmonization are also reshaping market competition. Imaging analysis historically depended heavily on operator expertise, manual segmentation, and modality-specific processing. New software environments increasingly automate reconstruction, co-registration, image fusion, quantitative interpretation, and data organization across multiple instruments. AI-enabled multimodal analysis introduced during 2025 highlighted the industry's move toward faster and more reproducible preclinical workflows. In parallel, GPU-supported PET reconstruction is improving processing speed, while modern micro-CT systems can perform whole-body mouse imaging in approximately 5 seconds at doses near 2 mGy under selected protocols. Photoacoustic imaging is advancing through combined ultrasound-photoacoustic platforms that support deeper functional and molecular characterization. These improvements are particularly important for longitudinal studies because researchers seek to observe the same animal repeatedly without excessive radiation exposure or inconsistent processing. Consequently, instrument performance is increasingly evaluated not only by raw spatial resolution but also by workflow automation, throughput, quantitative accuracy, multimodal interoperability, and ease of operation.

Market Dynamics

Driver

""Expanding translational drug research is accelerating adoption of advanced in vivo imaging.""

Growth in pharmaceutical discovery, biotechnology pipelines, precision medicine, oncology research, neuroscience, and targeted therapies is increasing demand for preclinical imaging because researchers need non-invasive methods for tracking disease progression and therapeutic effects over time. Longitudinal imaging allows multiple measurements from the same subject, improving statistical consistency while supporting the 3Rs principle of reducing, refining, and replacing animal use where possible. The market's projected increase from USD 2807.75 million in 2026 to USD 4429.95 million by 2035 reflects the growing role of imaging in translational decision-making. PET and SPECT provide molecular and functional information, MRI offers high soft-tissue contrast without ionizing radiation, CT delivers detailed structural information, and optical or ultrasound techniques can enable comparatively rapid screening. Hybrid imaging further strengthens study design by allowing anatomical and molecular information to be evaluated together. As developers pursue increasingly complex biologics, cell therapies, radiopharmaceuticals, immunotherapies, and precision treatments, preclinical imaging is becoming more embedded in efficacy assessment, biodistribution analysis, toxicity evaluation, target validation, and biomarker development.

Restraint

""High acquisition and operating complexity can restrict adoption among smaller laboratories.""

Advanced preclinical imaging equipment requires substantial capital expenditure, specialized installation conditions, trained personnel, maintenance contracts, calibration procedures, image-processing expertise, and in some cases radiation-handling infrastructure. High-field MRI platforms can require carefully controlled environments and experienced operators, while PET and SPECT research involves radiotracer production, handling, licensing, and radioactive waste procedures. Even compact multimodal systems can involve several hardware components and sophisticated software environments. These requirements can discourage smaller academic laboratories and early-stage biotechnology companies from purchasing dedicated equipment, leading them instead to use shared imaging cores or outsourced services. Operational complexity becomes more significant when researchers require 2 or more modalities within the same study because accurate co-registration, standardized animal positioning, anesthesia management, physiological monitoring, and cross-platform quantification must be maintained. The challenge is particularly pronounced in emerging research environments where specialized imaging expertise remains limited. Manufacturers are responding through benchtop formats, turnkey workflows, cryogen-free magnets, simplified interfaces, and automated reconstruction, but purchasing decisions still depend heavily on anticipated utilization rates and long-term research funding.

Opportunity

""AI, compact platforms, and emerging research centers create substantial expansion potential.""

A major market opportunity is emerging from the convergence of artificial intelligence, modular hardware, advanced image reconstruction, radiopharmaceutical development, and laboratory expansion in Asia-Pacific and other developing research regions. Compact PET, SPECT, and CT instruments lower space and infrastructure barriers while allowing laboratories to add modules as research programs grow. Platforms with more than 250 installations demonstrate that scalable systems can attract users beyond traditional large imaging centers. AI-enabled software creates another opportunity by automating image segmentation, multimodal alignment, data interpretation, and repetitive analysis tasks that previously required extensive specialist involvement. Demand is also increasing in targeted radionuclide therapy research, where high-sensitivity PET and SPECT technologies can evaluate novel isotopes and biodistribution patterns before clinical translation. The overall market is expected to expand approximately 5.2% annually from 2026 through 2035, but emerging markets and specialized imaging niches may grow more rapidly. Vendors capable of offering integrated hardware, reagents, software, analytics, training, and technical services can therefore capture a larger share of research spending while improving customer retention.

Challenge

""Maintaining reproducibility across complex multimodal studies remains a technical challenge.""

Preclinical imaging laboratories increasingly generate high-dimensional datasets from MRI, CT, PET, SPECT, optical, ultrasound, and photoacoustic studies, making standardization and reproducibility a central market challenge. A single longitudinal experiment can involve several imaging sessions, multiple animals, different tracers, physiological monitoring data, and repeated reconstruction or segmentation procedures. Small changes in anesthesia, positioning, temperature, acquisition timing, detector calibration, reconstruction settings, or image-processing parameters can influence quantitative outcomes. Multimodal studies further require accurate registration between modalities with substantially different spatial resolutions and biological signals. Modern PET systems can reach approximately 0.7 mm resolution, while specialized micro-CT technologies can achieve resolution measured in tens of micrometers, creating significant data-integration requirements. Laboratories therefore need robust software, standardized protocols, trained operators, and disciplined data governance. AI may reduce some variability, but algorithms also require validation to ensure outputs remain consistent across research models and institutions. Vendors that simplify calibration, automate corrections, standardize workflows, and provide transparent quantitative tools will have an advantage as reproducibility becomes an increasingly important purchasing criterion.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The preclinical imaging market is segmented by product type into CT Imaging, MRI Imaging, PET/SPECT Imaging, Multi-modal Imaging, Optical Imaging, Ultrasound Imaging, Photoacoustic Imaging, Reagents, and Services. By application, the market is divided into Hospital, Diagnostics Center, and Others. Demand differs substantially according to research objective, required spatial or temporal resolution, available laboratory infrastructure, imaging depth, biomarker strategy, and whether studies emphasize structural, functional, or molecular endpoints.

By Types

CT Imaging: CT Imaging is estimated to represent approximately 13% of market demand. Micro-CT is widely used for high-resolution structural evaluation of bone, lung, cardiovascular structures, implanted materials, tumors, and anatomical changes. Modern systems support rapid acquisition and low-dose longitudinal protocols, with selected platforms completing whole-body mouse scans in around 5 seconds and providing resolution down to approximately 30 µm for many high-resolution workflows. CT also plays an important supporting role within PET/CT and SPECT/CT configurations because it supplies anatomical localization and attenuation-correction information. Improvements in detector technology, dose reduction, dynamic contrast analysis, and automated reconstruction are increasing research value while reducing the limitations associated with repeated radiation exposure.

MRI Imaging: MRI Imaging is estimated to hold approximately 22% market share, making it one of the largest individual product categories. Preclinical MRI is valued for excellent soft-tissue contrast, multiparametric imaging, functional assessment, diffusion analysis, spectroscopy, neuroimaging, cardiovascular research, and repeated studies without ionizing radiation. High-field instruments commonly operate at 7 T and 9.4 T, enabling detailed investigation of small-animal anatomy and physiology. Advances in cryogen-efficient or cryogen-free designs, specialized coils, stronger gradients, automated acquisition, and integrated PET inserts are widening the modality's application base. MRI remains especially important in neuroscience, oncology, brain tumor research, stroke models, cardiac imaging, musculoskeletal studies, and evaluation of emerging therapeutic approaches where precise longitudinal measurements are required.

PET/SPECT Imaging: PET/SPECT Imaging accounts for an estimated 15% share as molecular imaging becomes increasingly important for tracer development, biodistribution analysis, receptor studies, immuno-oncology, targeted radionuclide therapy, and pharmacokinetic research. PET offers high sensitivity for radiolabeled biomarkers, while SPECT supports a broad portfolio of radioisotopes and increasingly sophisticated theranostic applications. Modern preclinical PET systems can provide spatial resolution near 0.7 mm and sensitivity reaching approximately 12%, while specialized SPECT platforms can achieve sub-0.25 mm in vivo mouse resolution under suitable conditions. Growing pharmaceutical interest in radiopharmaceuticals and targeted therapies is creating demand for systems capable of quantitative imaging at very low tracer concentrations and across repeated experimental time points.

Multi-modal Imaging: Multi-modal Imaging represents approximately 12% of the market and is expanding as researchers seek complementary structural, molecular, functional, and metabolic information from a coordinated experiment. PET/CT, PET/MR, SPECT/CT, PET/SPECT/CT, optical/CT, and other combinations improve localization and interpretation compared with isolated modality results. Advanced systems increasingly use unified animal beds and software to maintain registration across 2 or more modalities. Multimodal imaging supports oncology, neurobiology, immunology, cardiovascular research, and drug development by allowing biological changes to be examined from several perspectives. Adoption is also supported by modular systems that allow laboratories to begin with a single instrument and expand capability when additional funding or scientific needs arise.

Optical Imaging: Optical Imaging is estimated to account for approximately 10% of demand. Bioluminescence and fluorescence techniques are widely used because they can provide sensitive, relatively rapid, and cost-efficient assessment of reporter genes, tumor progression, cell trafficking, infectious disease models, molecular probes, and treatment response. Optical imaging is particularly suitable for high-throughput longitudinal studies involving multiple animals. Newer workflows combine optical information with CT data to improve anatomical localization and quantitative accuracy. Advanced spectral unmixing is also improving separation of overlapping fluorescent signals, strengthening the usefulness of optical techniques in complex biological experiments. Although penetration depth remains more limited than MRI or nuclear imaging, the modality retains significant value for screening and molecular biology.

Ultrasound Imaging: Ultrasound Imaging represents approximately 8% of market demand and is widely applied in cardiovascular, developmental biology, oncology, reproductive research, and image-guided interventions. High-frequency preclinical ultrasound provides real-time imaging with strong temporal resolution, no ionizing radiation, and comparatively flexible laboratory operation. Improvements in transducer technology, Doppler modes, three-dimensional acquisition, automated measurements, and integration with photoacoustic imaging are expanding applications. Ultrasound is particularly valuable where researchers need repeated physiological measurements, vascular assessment, cardiac function analysis, or real-time guidance. Combined ultrasound and photoacoustic systems are further strengthening its role by linking anatomical information with blood oxygenation, vascularity, molecular contrast, and tissue-composition measurements.

Photoacoustic Imaging: Photoacoustic Imaging accounts for an estimated 5% market share but is among the technologically dynamic segments. It combines optical excitation with ultrasound detection to evaluate tissue oxygenation, hemoglobin distribution, vascular structures, molecular probes, and functional biological processes at greater depths than conventional optical imaging. In June 2025, a multimodal preclinical platform combining high-frequency ultrasound with advanced photoacoustic capabilities was introduced to address oncology, cardiovascular, neurobiology, and molecular biology applications. Continued improvements in laser technology, wavelength selection, acquisition speed, and integrated analysis are expected to increase adoption. The segment remains smaller than MRI or CT but benefits from growing demand for non-ionizing functional and molecular imaging.

Reagents: Reagents represent approximately 9% of the market and include contrast agents, fluorescent probes, radiotracers, molecular imaging agents, and specialized compounds used to visualize biological targets. Reagent demand is closely connected to instrument utilization because many molecular imaging studies require target-specific probes or contrast enhancement. Growth in immuno-PET, targeted radionuclide therapy, oncology biomarkers, neuroscience, inflammation research, and cell-tracking applications is expanding the range of specialized imaging agents. Emerging isotopes such as actinium-225 and lead-212 are also creating opportunities for advanced nuclear imaging research. Because reagents are consumed repeatedly during experiments rather than purchased as durable equipment, this segment provides recurring demand throughout the operational life of installed imaging systems.

Services: Services account for approximately 6% of market activity and include instrument maintenance, installation, training, imaging-as-a-service, protocol development, image analysis, data processing, and outsourced research support. Service demand is increasing as laboratories adopt technically sophisticated systems but seek to avoid maintaining expertise across every modality internally. Smaller biotechnology companies frequently access academic imaging cores or contract research providers rather than purchasing dedicated high-field MRI or nuclear imaging equipment. Service providers also support study design, quantitative analysis, standardized reconstruction, and regulatory-quality documentation. As multimodal imaging and AI-enabled analysis become more complex, specialized technical support is expected to remain an important component of customer relationships and equipment lifecycle management.

By Applications

Hospital: Hospital applications are estimated to represent approximately 46% of preclinical imaging demand. Major academic hospitals and medical research centers operate translational laboratories that connect basic science with clinical programs in oncology, neurology, cardiology, metabolic disease, immunology, and regenerative medicine. These institutions often maintain centralized imaging facilities containing several modalities because researchers require access to MRI, CT, PET, SPECT, optical, ultrasound, and image-analysis technologies. Hospital-affiliated laboratories are also positioned to evaluate imaging biomarkers and therapeutic approaches that may transition into human trials. Their strong research infrastructure, multidisciplinary expertise, and access to clinical imaging knowledge support continued investment in high-performance systems and integrated quantitative workflows.

Diagnostics Center: Diagnostics Center applications account for an estimated 31% share. Specialized imaging and research centers serve pharmaceutical developers, biotechnology companies, universities, and other organizations requiring advanced imaging without establishing dedicated facilities. These centers benefit from high equipment utilization and can maintain specialized expertise across multiple modalities. Growth is supported by increasing outsourcing of drug-development activities and demand for standardized imaging endpoints across multicenter studies. Diagnostic and imaging centers may operate PET/CT, SPECT/CT, MRI, optical, or ultrasound platforms and provide quantitative interpretation, tracer support, and longitudinal study services. As preclinical research becomes more data-intensive, centers capable of offering integrated acquisition and analysis are positioned to capture additional outsourced demand.

Others: Others represent approximately 23% of market demand and include universities, pharmaceutical companies, biotechnology organizations, contract research laboratories, government institutes, veterinary research organizations, and independent academic facilities. Pharmaceutical and biotechnology laboratories increasingly use preclinical imaging for efficacy testing, biodistribution analysis, toxicity assessment, target validation, and biomarker development. Academic institutions remain important users because imaging technologies support research across numerous disciplines. Contract research organizations provide access to sophisticated equipment for companies that prefer variable operating expenditure instead of capital ownership. Demand within this application group is expected to broaden as compact benchtop systems, outsourced services, software automation, and multimodal workflows make advanced imaging accessible to a wider research community.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to hold approximately 39% of the global preclinical imaging market in 2026, making it the leading regional market. The United States contributes most of the regional demand because it hosts a large concentration of pharmaceutical manufacturers, biotechnology firms, medical research universities, cancer centers, neuroscience institutes, and contract research organizations. High research expenditure and early adoption of sophisticated instrumentation support demand for MRI, PET/SPECT, CT, optical, ultrasound, and multimodal technologies. Laboratories increasingly require imaging systems that support quantitative longitudinal research while reducing animal numbers and improving translational relevance. Demand is particularly strong for oncology, neuroscience, radiopharmaceutical, metabolic, cardiovascular, and immunology studies.

The region also benefits from strong technology availability and substantial installed infrastructure. U.S. imaging centers are among the earliest adopters of advanced PET/CT, PET/MR, high-field MRI, AI-supported analysis, and automated reconstruction. Academic and commercial facilities increasingly emphasize high-throughput research, standardized datasets, and interoperability between modalities. Canada contributes through university research, biotechnology development, and imaging innovation, particularly in ultrasound and photoacoustic research. North American market growth is expected to remain steady through 2035 as precision medicine and targeted therapies increase demand for sophisticated preclinical validation. Despite relatively mature equipment penetration, replacement cycles, software upgrades, new imaging agents, and growing use of multimodal workflows will continue creating opportunities for suppliers.

Europe

Europe is estimated to account for approximately 28% of global market demand in 2026. Germany, the United Kingdom, France, the Netherlands, Italy, Belgium, Switzerland, and Nordic countries maintain strong biomedical research capabilities and extensive networks of universities, pharmaceutical companies, research hospitals, and specialized imaging centers. The region benefits from established expertise in MRI, molecular imaging, radiopharmaceuticals, multimodal research, and quantitative imaging. European institutions increasingly apply preclinical imaging to oncology, neuroscience, cardiovascular disease, inflammation, infectious disease, and targeted radionuclide therapy. Demand for low-dose imaging and longitudinal study designs is also supported by strong emphasis on animal welfare and the 3Rs framework.

European suppliers and research institutions are actively advancing modular PET/SPECT/CT architectures, cryogen-free MRI technology, high-resolution nuclear imaging, image reconstruction, and multimodal quantification. The Netherlands is particularly active in high-resolution SPECT and CT research, while the United Kingdom maintains substantial expertise in preclinical MRI and molecular imaging. Germany remains a major research and pharmaceutical market, supported by extensive academic and industrial R&D. Europe is also benefiting from increasing interest in theranostics and novel radionuclides, which require sensitive preclinical imaging for biodistribution and dosimetry studies. Although public research-budget pressure can influence procurement timing, collaborative research programs and shared imaging facilities help sustain equipment utilization and investment.

Asia-Pacific

Asia-Pacific is estimated to represent approximately 27% of the market in 2026 and is expected to record the fastest expansion, with growth near 6.4% annually during the forecast period. China, Japan, South Korea, India, Australia, and Singapore are strengthening pharmaceutical R&D, biotechnology investment, university research, and translational medicine infrastructure. Increasing numbers of research laboratories are adopting micro-CT, MRI, optical imaging, ultrasound, PET/SPECT, and multimodal instruments as regional drug-development capabilities mature. China has expanded biomedical research capacity considerably, while Japan maintains strong pharmaceutical, imaging, and academic research expertise. South Korea and Singapore are investing in precision medicine and advanced life-science research, supporting adoption of quantitative preclinical platforms.

India is also developing as an important future opportunity as pharmaceutical manufacturing, biosimilars, contract research, and biotechnology ecosystems expand. Cost sensitivity remains stronger than in North America or Western Europe, encouraging demand for modular systems, shared facilities, contract imaging, and scalable equipment configurations. Benchtop systems that require less laboratory space may therefore have particular appeal. Asia-Pacific's share could gradually increase through 2035 as local research institutions strengthen funding and international pharmaceutical companies expand regional R&D partnerships. Vendors that provide local technical service, training, application development, and affordable maintenance are likely to achieve stronger market penetration than companies relying solely on premium hardware sales.

Middle East & Africa

Middle East & Africa is estimated to account for approximately 6% of the global market in 2026. Market demand is concentrated in major academic medical centers, government-funded research organizations, pharmaceutical laboratories, and universities in countries such as Saudi Arabia, the United Arab Emirates, Israel, South Africa, and selected Gulf states. Regional institutions increasingly invest in biomedical research, cancer studies, precision medicine, genomics, neuroscience, and advanced diagnostic infrastructure. However, high equipment acquisition costs, limited numbers of specialized operators, and uneven access to radiotracer infrastructure continue to restrict adoption compared with North America, Europe, and Asia-Pacific.

Future growth is expected to come from government healthcare modernization programs, new university research campuses, international scientific partnerships, and centralized imaging facilities capable of serving multiple institutions. Compact and modular imaging systems may have particular value because they reduce space requirements and can be expanded as research demand increases. Service models and outsourced analysis may also help overcome shortages of specialized technical expertise. Over the forecast period, regional adoption should gradually broaden from major flagship institutions to a larger group of biomedical laboratories. Suppliers offering training, remote support, installation assistance, and simplified software platforms are expected to be better positioned for sustainable expansion in the region.

List of Top Preclinical Imaging Companies

• Bruker Corporation: Bruker maintains a broad preclinical imaging portfolio covering MRI, micro-CT, PET, SPECT, optical imaging, multimodal platforms, and quantitative software. Its compact modular CUBES platform has surpassed 250 installations worldwide, while PET/CT systems can achieve approximately 0.7 mm PET resolution and sensitivity approaching 12%.
• Siemens A.G.: Siemens contributes extensive medical-imaging expertise and technology knowledge relevant to translational and research environments, particularly in molecular imaging, MRI, CT, reconstruction, digital workflows, and imaging informatics used across academic and pharmaceutical research ecosystems.
• General Electric (GE): GE participates through advanced imaging technologies and research-oriented systems that support anatomical, molecular, and functional imaging workflows, benefiting from extensive expertise in MRI, CT, PET, image reconstruction, and clinical-to-preclinical translational research.
• TriFoil Imaging: TriFoil Imaging focuses on small-animal imaging technologies for laboratory research, including molecular and anatomical solutions designed for pharmaceutical, academic, and biotechnology applications requiring compact configurations and dedicated preclinical workflows.
• PerkinElmer, Inc.: PerkinElmer has historically established a strong position in optical and in vivo imaging workflows, supporting fluorescence and bioluminescence applications that enable longitudinal research, tumor tracking, molecular analysis, and drug-development studies involving multiple experimental subjects.
• VisualSonics Inc. (Fujifilm): VisualSonics specializes in high-frequency ultrasound and photoacoustic imaging. In June 2025, its multimodal Vevo F2 LAZR-X20 platform expanded preclinical capabilities across oncology, cardiovascular, neurobiology, and molecular biology research.
• Mediso Ltd.: Mediso develops molecular imaging systems used in preclinical and translational research, including PET, SPECT, CT, and multimodality configurations that support radiopharmaceutical studies and quantitative imaging of disease models.
• Agilent Technologies: Agilent Technologies participates in life-science research through analytical and imaging-related technologies, supporting laboratories that require integrated research infrastructure, quantitative workflows, and advanced instrumentation across drug-development programs.
• MILabs B.V.: MILabs specializes in high-resolution SPECT, PET, CT, optical, and multimodal preclinical imaging systems. Its SPECT technology can achieve sub-0.25 mm in vivo total-body mouse resolution under appropriate configurations, supporting demanding molecular and theranostic research.
• MR Solutions: MR Solutions develops cryogen-free preclinical MRI and multimodal systems, including PET/MR platforms reaching 9.4 T and accommodating animals up to approximately 3 kg. Its portfolio supports laboratories requiring flexible MRI, PET, CT, and integrated workflows.
• Molecubes: Molecubes focuses on compact modular PET, SPECT, and CT technologies designed to reduce barriers associated with laboratory space and complex infrastructure. Its benchtop architecture supports scalable molecular imaging and straightforward integration into existing research facilities.

Top 2 Companies Market Share

Bruker Corporation: Bruker Corporation is estimated to account for approximately 15% of competitive market activity, supported by its broad portfolio spanning high-field MRI, micro-CT, PET, SPECT, optical technologies, multimodal systems, software, animal-handling solutions, and quantitative analysis. The company benefits from the ability to serve both specialized imaging centers and laboratories seeking modular configurations. Its installed base of more than 250 CUBES systems illustrates growing adoption of compact preclinical molecular imaging. Continued development of BioSpec, PET/CT, ParaVision, Clarity reconstruction, PMOD integration, and modular systems strengthens Bruker's position across oncology, neuroscience, metabolic research, radiopharmaceutical development, and translational medicine.

VisualSonics Inc. (Fujifilm): VisualSonics Inc. (Fujifilm) is estimated to represent approximately 9% of competitive market activity, with particularly strong positioning in high-frequency ultrasound and photoacoustic imaging. Its technology serves cardiovascular, oncology, neurobiology, developmental biology, and molecular imaging research where real-time, non-ionizing measurements are valuable. The June 2025 introduction of the Vevo F2 LAZR-X20 strengthened its multimodal strategy by integrating advanced ultrasound and photoacoustic capabilities. Increasing interest in vascular imaging, tissue oxygenation, functional analysis, and repeated longitudinal measurements should support continued adoption among research institutions seeking complementary alternatives to MRI, CT, and nuclear imaging.

Investment Analysis

Investment in the preclinical imaging market is increasingly directed toward technologies that improve throughput, reduce operational complexity, strengthen quantitative reproducibility, and connect preclinical findings more directly with clinical development. The projected increase from USD 2807.75 million in 2026 to USD 4429.95 million by 2035 provides a favorable environment for equipment modernization, software development, reagent innovation, laboratory expansion, and outsourced imaging services. Investors and research institutions are showing particular interest in multimodal systems because a single experimental subject can be assessed using 2 or more complementary technologies, potentially increasing information generated per study. Compact PET, SPECT, and CT architectures can also improve capital efficiency by allowing laboratories to begin with one modality before adding additional capabilities. Software represents another attractive investment area as automated reconstruction, image fusion, segmentation, AI-assisted analysis, and cloud-compatible data management can increase utilization of installed hardware without requiring proportional expansion of laboratory staffing.

Geographically, North America and Europe remain important investment destinations because they contain mature pharmaceutical and academic research networks, while Asia-Pacific offers stronger incremental expansion potential. The region's estimated 6.4% annual growth creates opportunities in local distribution, technical service, imaging-core development, reagent supply, and contract research. Radiopharmaceutical research is another emerging investment focus as targeted radionuclide therapies require sensitive PET and SPECT imaging during compound development, biodistribution assessment, dosimetry, and translational validation. Low-dose CT, cryogen-free MRI, photoacoustic imaging, high-frequency ultrasound, advanced optical systems, and AI-enabled analysis are also attracting development resources. Companies able to combine hardware with recurring software upgrades, reagents, maintenance, training, and analytical services can potentially create more durable customer relationships than vendors focused exclusively on one-time equipment sales.

New Product Development

New product development is emphasizing integration rather than isolated improvements in individual modalities. Manufacturers are designing systems that combine imaging hardware, animal handling, reconstruction, co-registration, analysis, and data management within unified workflows. Bruker's current portfolio illustrates this direction through PET/MR, PET/CT, compact PET/SPECT/CT systems, advanced MRI, and integrated software. Its PET/CT Si78 combines approximately 0.7 mm PET resolution, sensitivity up to 12%, an axial field of view around 150 mm, and low-dose CT functionality. Modern reconstruction software increasingly uses GPU processing to provide faster feedback and consistent quantitative results. MRI development is similarly moving toward streamlined high-field systems, broader sequence libraries, advanced spectroscopy, automated workflow controls, and configurations that reduce cryogen dependence. These features address laboratory requirements for higher throughput and more reproducible research without sacrificing sensitivity or spatial resolution.

Innovation in ultrasound, photoacoustic imaging, molecular imaging, and AI-enabled analytics is creating additional product-development opportunities. VisualSonics introduced the Vevo F2 LAZR-X20 in June 2025 as a multimodal photoacoustic and ultrasound platform aimed at multiple preclinical research fields. MILabs continues to advance high-sensitivity nuclear imaging and has demonstrated research applications involving isotopes such as actinium-225 and lead-212, reflecting growing interest in theranostics. Software development is becoming equally important because laboratories need faster segmentation, multimodal alignment, standardized analysis, and more reproducible quantitative outputs. AI-based multimodal imaging software released in September 2025 demonstrated how the sector is moving toward automated interpretation across optical, micro-CT, ultrasound, and related datasets. Future development is expected to prioritize lower radiation exposure, higher detector sensitivity, automated protocols, compact footprints, real-time reconstruction, improved molecular probes, and stronger interoperability between imaging modalities.

Five Recent Developments

• April 2026: Bruker presented an expanded multimodal preclinical imaging workflow at the Preclinical Imaging Consortium meeting, highlighting BioSpec Maxwell MRI, SPECT CUBE, optical imaging, PET/CT, Dynamis metabolic imaging, and integrated quantitative software within a coordinated research ecosystem.
• January 2026: MILabs highlighted direct preclinical imaging of lead-212 using high-sensitivity VECTor/CT, strengthening the role of advanced SPECT/CT technologies in targeted radionuclide therapy and emerging theranostic research involving difficult-to-image isotopes.
• September 2025: AI-enabled multimodal analysis software was introduced for preclinical in vivo imaging workflows, supporting more standardized analysis across optical, micro-CT, ultrasound, and other imaging data while increasing emphasis on throughput and reproducibility.
• June 2025: VisualSonics Inc. (Fujifilm) launched the Vevo F2 LAZR-X20 Photoacoustic Imaging Platform, combining ultrasound and photoacoustic functionality for oncology, cardiovascular, neurobiology, and molecular biology studies requiring anatomical and functional characterization.
• September 2024: MR Solutions installed a PET scanner at the Mary Lyon Centre, reflecting continued investment in dedicated preclinical molecular imaging infrastructure and increased availability of PET technology for longitudinal biological and translational research programs.

Report Coverage

The Preclinical Imaging Market report evaluates industry conditions across CT Imaging, MRI Imaging, PET/SPECT Imaging, Multi-modal Imaging, Optical Imaging, Ultrasound Imaging, Photoacoustic Imaging, Reagents, and Services while assessing demand from Hospital, Diagnostics Center, and Others applications. The analysis incorporates the market trajectory from USD 2668.96 million in 2025 to USD 2807.75 million in 2026 and USD 4429.95 million by 2035, representing a projected CAGR of 5.2%. Product analysis considers spatial resolution, sensitivity, radiation exposure, imaging depth, throughput, multimodal integration, longitudinal research capability, data-analysis requirements, laboratory infrastructure, and operating complexity. Application coverage examines how translational research centers, imaging facilities, pharmaceutical laboratories, biotechnology organizations, universities, and other research institutions deploy preclinical imaging technologies to evaluate disease progression, therapeutic response, biodistribution, biomarkers, functional changes, and anatomical outcomes.

The geographic assessment covers North America with an estimated 39% share, Europe with 28%, Asia-Pacific with 27%, and Middle East & Africa with 6%, providing a complete 100% regional distribution framework. Competitive coverage includes Bruker Corporation, Siemens A.G., General Electric (GE), TriFoil Imaging, PerkinElmer, Inc., VisualSonics Inc. (Fujifilm), Mediso Ltd., Agilent Technologies, MILabs B.V., MR Solutions, and Molecubes. The report evaluates market drivers, restraints, opportunities, challenges, investment conditions, product-development strategies, recent industry activity, and competitive differentiation. Particular attention is given to multimodal platforms, high-field MRI, high-sensitivity PET/SPECT, low-dose micro-CT, photoacoustic imaging, compact benchtop architectures, advanced molecular probes, AI-enabled analysis, GPU reconstruction, standardized quantitative workflows, and the growing use of longitudinal imaging. These factors collectively define the industry's development direction through 2035 as research organizations seek faster, more reproducible, information-rich, and clinically relevant preclinical studies.